Further bolstering its ambitious vaccine program, Pfizer has teamed up with Cytos Biotechnology to develop, manufacture and commercialize vaccines for a defined number of human diseases. Cytos gains CHF 10 million up-front and up to CHF 140 in possible additional milestones. The company could also score research funding and royalties on any products that make it to market. The deal incorporates specific disease targets which are outside the scope of Cytos' own programs.
--read the report in FierceBiotech